These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 15118874)

  • 1. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
    Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
    Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
    Thon N; Eigenbrod S; Grasbon-Frodl EM; Ruiter M; Mehrkens JH; Kreth S; Tonn JC; Kretzschmar HA; Kreth FW
    J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
    Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
    Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling and subgroup identification of oligodendrogliomas.
    Huang H; Okamoto Y; Yokoo H; Heppner FL; Vital A; Fevre-Montange M; Jouvet A; Yonekawa Y; Lazaridis EN; Kleihues P; Ohgaki H
    Oncogene; 2004 Aug; 23(35):6012-22. PubMed ID: 15208679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.
    Yang P; Kollmeyer TM; Buckner K; Bamlet W; Ballman KV; Jenkins RB
    Cancer; 2005 Jun; 103(11):2363-72. PubMed ID: 15834925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status.
    Fathi AR; Vassella E; Arnold M; Curschmann J; Reinert M; Vajtai I; Weis J; Deiana G; Mariani L
    Strahlenther Onkol; 2007 Sep; 183(9):517-22. PubMed ID: 17762927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.